Pieris Pharma (PIRS) Acquires License from Enumeral Biomedical

 

Pieris Pharma (NASDAQ: PIRS) disclosed that on April 18, 2016, that it and Pieris Pharmaceuticals GmbH, a wholly-owned subsidiary of the Company, entered into a license and transfer agreement with Enumeral Biomedical Holdings, Inc., pursuant to which Pieris acquired a non-exclusive (except in the exclusive field described below) worldwide license to use specified patent rights and know-how owned by Enumeral to research, develop and market fusion proteins consisting of PD-1 antibodies linked to one or more Anticalin proteins for use in the oncology area. Enumeral also agreed not to practice or assist third parties in practicing in the exclusive field, consisting of licensed antibodies fused to Anticalin proteins in the oncology area.

Subscribe to get the latest news